AU2016321659A1 - Formulation having controlled, delayed active-ingredient release - Google Patents
Formulation having controlled, delayed active-ingredient release Download PDFInfo
- Publication number
- AU2016321659A1 AU2016321659A1 AU2016321659A AU2016321659A AU2016321659A1 AU 2016321659 A1 AU2016321659 A1 AU 2016321659A1 AU 2016321659 A AU2016321659 A AU 2016321659A AU 2016321659 A AU2016321659 A AU 2016321659A AU 2016321659 A1 AU2016321659 A1 AU 2016321659A1
- Authority
- AU
- Australia
- Prior art keywords
- release
- active ingredient
- tablet
- tablets
- propranolol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 158
- 239000000203 mixture Substances 0.000 title claims abstract description 151
- 238000009472 formulation Methods 0.000 title claims abstract description 46
- 230000003111 delayed effect Effects 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 134
- 238000013265 extended release Methods 0.000 claims description 76
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 61
- 229960003712 propranolol Drugs 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 36
- 229960000278 theophylline Drugs 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 20
- 239000002876 beta blocker Substances 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 11
- 229940097320 beta blocking agent Drugs 0.000 claims description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
- 230000036470 plasma concentration Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 5
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000000704 physical effect Effects 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 229940120120 innopran Drugs 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 124
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 93
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 93
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 72
- 238000007906 compression Methods 0.000 claims 65
- 230000006835 compression Effects 0.000 claims 65
- 235000019589 hardness Nutrition 0.000 claims 47
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 30
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 26
- 239000002245 particle Substances 0.000 claims 22
- 238000000338 in vitro Methods 0.000 claims 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 17
- 238000005259 measurement Methods 0.000 claims 16
- 235000019359 magnesium stearate Nutrition 0.000 claims 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 12
- 239000000047 product Substances 0.000 claims 11
- 238000009826 distribution Methods 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000377 silicon dioxide Substances 0.000 claims 9
- 235000012239 silicon dioxide Nutrition 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 238000013270 controlled release Methods 0.000 claims 8
- 239000000314 lubricant Substances 0.000 claims 8
- 235000019888 Vivapur Nutrition 0.000 claims 7
- 238000005299 abrasion Methods 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 7
- 238000012512 characterization method Methods 0.000 claims 7
- 238000011161 development Methods 0.000 claims 7
- 238000000227 grinding Methods 0.000 claims 7
- 238000000691 measurement method Methods 0.000 claims 7
- 238000002156 mixing Methods 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000000654 additive Substances 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 238000011156 evaluation Methods 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 239000008188 pellet Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 claims 5
- 230000001186 cumulative effect Effects 0.000 claims 5
- 238000009792 diffusion process Methods 0.000 claims 5
- 230000003628 erosive effect Effects 0.000 claims 5
- 238000002474 experimental method Methods 0.000 claims 5
- 239000007903 gelatin capsule Substances 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229960004604 propranolol hydrochloride Drugs 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 4
- 230000036772 blood pressure Effects 0.000 claims 4
- 238000007907 direct compression Methods 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 230000007062 hydrolysis Effects 0.000 claims 4
- 238000006460 hydrolysis reaction Methods 0.000 claims 4
- 239000008363 phosphate buffer Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 239000011369 resultant mixture Substances 0.000 claims 4
- 239000007916 tablet composition Substances 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 238000007792 addition Methods 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000007891 compressed tablet Substances 0.000 claims 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims 3
- 239000000416 hydrocolloid Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000011148 porous material Substances 0.000 claims 3
- 238000012545 processing Methods 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 238000005070 sampling Methods 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 238000005303 weighing Methods 0.000 claims 3
- AQHHHDLHHXJYJD-AWEZNQCLSA-N (2s)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2C(OC[C@@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-AWEZNQCLSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000012369 In process control Methods 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 239000011362 coarse particle Substances 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 239000007902 hard capsule Substances 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000006872 improvement Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000011068 loading method Methods 0.000 claims 2
- 229920002521 macromolecule Polymers 0.000 claims 2
- IAVGMIBOMLTFSU-UHFFFAOYSA-L magnesium dioxosilane octadecanoate Chemical compound [Mg+2].O=[Si]=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O IAVGMIBOMLTFSU-UHFFFAOYSA-L 0.000 claims 2
- 239000013563 matrix tablet Substances 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 2
- 238000007873 sieving Methods 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- 239000004408 titanium dioxide Substances 0.000 claims 2
- 235000010215 titanium dioxide Nutrition 0.000 claims 2
- 235000013311 vegetables Nutrition 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 1
- 241000239290 Araneae Species 0.000 claims 1
- 238000004438 BET method Methods 0.000 claims 1
- 229920003043 Cellulose fiber Polymers 0.000 claims 1
- 241000905957 Channa melasoma Species 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000006057 Non-nutritive feed additive Substances 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000005903 acid hydrolysis reaction Methods 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960002274 atenolol Drugs 0.000 claims 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 229960002781 bisoprolol Drugs 0.000 claims 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007963 capsule composition Substances 0.000 claims 1
- 229960004195 carvedilol Drugs 0.000 claims 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims 1
- 150000003943 catecholamines Chemical class 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 230000002057 chronotropic effect Effects 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000013065 commercial product Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000002706 dry binder Substances 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010579 first pass effect Methods 0.000 claims 1
- -1 for example Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000010965 in-process control Methods 0.000 claims 1
- 238000009776 industrial production Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 238000011835 investigation Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000004407 iron oxides and hydroxides Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 229960002237 metoprolol Drugs 0.000 claims 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 229960004255 nadolol Drugs 0.000 claims 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000011236 particulate material Substances 0.000 claims 1
- 229960002035 penbutolol Drugs 0.000 claims 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000012429 release testing Methods 0.000 claims 1
- 238000007127 saponification reaction Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 229910001220 stainless steel Inorganic materials 0.000 claims 1
- 239000010935 stainless steel Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 238000009492 tablet coating Methods 0.000 claims 1
- 239000002700 tablet coating Substances 0.000 claims 1
- 229960004674 theophylline anhydrous Drugs 0.000 claims 1
- 229960005196 titanium dioxide Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 description 3
- 240000003517 Elaeocarpus dentatus Species 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930002161 purine alkaloid Natural products 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15185028.6 | 2015-09-14 | ||
| EP15185028 | 2015-09-14 | ||
| EP15189045 | 2015-10-09 | ||
| EP15189045.6 | 2015-10-09 | ||
| PCT/EP2016/001430 WO2017045742A1 (de) | 2015-09-14 | 2016-08-25 | Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016321659A1 true AU2016321659A1 (en) | 2018-05-10 |
Family
ID=56855404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016321659A Abandoned AU2016321659A1 (en) | 2015-09-14 | 2016-08-25 | Formulation having controlled, delayed active-ingredient release |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10874615B2 (enExample) |
| EP (1) | EP3349733A1 (enExample) |
| JP (1) | JP6841819B2 (enExample) |
| KR (1) | KR20180052126A (enExample) |
| CN (1) | CN108024966A (enExample) |
| AU (1) | AU2016321659A1 (enExample) |
| CA (1) | CA2998422A1 (enExample) |
| WO (1) | WO2017045742A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160235709A1 (en) | 2012-08-31 | 2016-08-18 | Molecular product management LLC | Limited release lingual thioctic acid delivery systems |
| JP7238509B2 (ja) * | 2019-03-19 | 2023-03-14 | 三菱ケミカル株式会社 | 医薬錠剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58502097A (ja) * | 1981-12-18 | 1983-12-08 | キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド | ポリビニルアルコ−ルおよびポリエチレングリコ−ルの拡張性格子 |
| EP0359746B1 (en) * | 1987-03-25 | 1992-06-03 | E.I. Du Pont De Nemours And Company | Use of vinyl alcohol homopolymers and copolymers for tableting active materials |
| US6495656B1 (en) * | 1990-11-30 | 2002-12-17 | Eastman Chemical Company | Copolyesters and fibrous materials formed therefrom |
| ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
| US5838571A (en) * | 1996-01-29 | 1998-11-17 | Alza Corporation | Tablet press monitoring and controlling method and apparatus |
| AU2001273231A1 (en) * | 2000-07-06 | 2002-01-21 | Delsys Pharmaceutical Corporation | Method for formulating healthcare products with enhanced stability |
| GB0113841D0 (en) * | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
| US7022342B2 (en) * | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
| US20060099256A1 (en) * | 2002-11-27 | 2006-05-11 | Price James C | Microspheres and related processes and pharmaceutical compositions |
| US7241838B2 (en) * | 2003-12-19 | 2007-07-10 | Eastman Chemical Company | Blends of aliphatic-aromatic copolyesters with ethylene-vinyl acetate copolymers |
| US7368503B2 (en) * | 2003-12-22 | 2008-05-06 | Eastman Chemical Company | Compatibilized blends of biodegradable polymers with improved rheology |
| US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
| US9238073B2 (en) * | 2006-04-12 | 2016-01-19 | Wyeth Llc | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive |
| NZ584521A (en) * | 2007-10-10 | 2011-03-31 | Avantor Performance Mat Inc | Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof |
| PT2177213E (pt) * | 2008-09-17 | 2013-02-21 | Siegfried Ltd | Granulado contendo nicotina |
| EP2498764B1 (en) * | 2009-11-09 | 2017-09-06 | Spotlight Technology Partners LLC | Fragmented hydrogels |
| JP2013241341A (ja) * | 2012-05-17 | 2013-12-05 | Nisshin Kasei Kk | マトリックス製剤用基剤、及び該基剤を用いた徐放性製剤 |
| GB201412413D0 (en) * | 2014-07-11 | 2014-08-27 | Revolymer Uk Ltd | Encapsulated benefit agent particles |
| AU2015295847B2 (en) * | 2014-07-30 | 2020-06-18 | Merck Patent Gmbh | Pulverulent, directly compressible types of polyvinyl alcohol |
-
2016
- 2016-08-25 AU AU2016321659A patent/AU2016321659A1/en not_active Abandoned
- 2016-08-25 WO PCT/EP2016/001430 patent/WO2017045742A1/de not_active Ceased
- 2016-08-25 KR KR1020187010365A patent/KR20180052126A/ko not_active Withdrawn
- 2016-08-25 JP JP2018513528A patent/JP6841819B2/ja not_active Expired - Fee Related
- 2016-08-25 CA CA2998422A patent/CA2998422A1/en not_active Abandoned
- 2016-08-25 US US15/759,674 patent/US10874615B2/en active Active
- 2016-08-25 EP EP16760385.1A patent/EP3349733A1/de not_active Withdrawn
- 2016-08-25 CN CN201680053419.0A patent/CN108024966A/zh active Pending
-
2020
- 2020-04-21 US US16/854,516 patent/US20200246270A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3349733A1 (de) | 2018-07-25 |
| JP6841819B2 (ja) | 2021-03-10 |
| KR20180052126A (ko) | 2018-05-17 |
| WO2017045742A1 (de) | 2017-03-23 |
| CA2998422A1 (en) | 2017-03-23 |
| CN108024966A (zh) | 2018-05-11 |
| JP2018530538A (ja) | 2018-10-18 |
| US20190038562A1 (en) | 2019-02-07 |
| US10874615B2 (en) | 2020-12-29 |
| US20200246270A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3174530T3 (en) | DIRECT COMPATIBLE POLYVINYL ALCOHOLS | |
| US10828258B2 (en) | Directly compressible composition comprising microcrystalline cellulose | |
| Abdelkader et al. | Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation | |
| US11883399B2 (en) | Bromocriptine formulations | |
| CN107951853B (zh) | 一种盐酸普拉克索缓释药物组合物及其制备方法 | |
| US11040012B2 (en) | Pulverulent, directly compressible polyvinyl alcohol grades | |
| US20200246270A1 (en) | Formulation having controlled, delayed release of active ingredient | |
| JP2020510626A (ja) | 延長した活性物質送達を有する錠剤を製造するための直接打錠可能なマトリックス | |
| US20180250233A1 (en) | Tablets having media independent active substance delivery | |
| WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
| WO2012107090A1 (en) | Granulated composition comprising tadalafil and a disintegrant | |
| CN113827576B (zh) | 一种活性成分为草酸纳洛解的药物组合物及制备方法 | |
| JP7346404B2 (ja) | アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法 | |
| US20160022661A1 (en) | Dosage Form Comprising Crizotinib | |
| WO2021148362A1 (en) | Directly compressible polymer combinations for matrix tablets with extended drug release | |
| CN119868294A (zh) | 一种利格列汀药物组合物及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |